Caisson Transcatheter Mitral Valve Replacement (TMVR)

Mitral Regurgitation Clinical Trial

— INTERLUDE  

Official title:

Clinical Investigation of the Caisson Transcatheter Mitral Valve Replacement (TMVR) System for Percutaneous Mitral Valve Replacement in Patients With Symptomatic Mitral Regurgitation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03661398
• Other study ID #: INT-001
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 20, 2017
• Est. completion date: August 2025

Study information

• Verified date: January 2020
• Source: Caisson Interventional LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).

Description:

The treatment guidelines for valvular heart disease indicate that surgical correction of primary mitral valve regurgitation (MR) is a Class I recommendation. Recent evidence indicates that valve replacement is at least as effective as repair in both primary and secondary MR patients. However, many patients are not referred for surgery as they are considered to be too high of a risk to undergo on-pump, open-heart procedures. Percutaneous aortic valve replacement has made treatment of stenosed aortic valves available to high-risk surgical patients who would have otherwise been medically managed. Percutaneous mitral valve (MV) replacement offers similar advantages. The feasibility of percutaneous MV replacement has been demonstrated in early feasibility studies. To meet this medical need, Caisson Interventional has developed a percutaneous delivery system for a bioprosthetic mitral valve. As with patients with aortic valve (AV) deficiencies, this device can be used to provide needed therapy to patients who might not otherwise receive treatment beyond medical therapy. This study will provide information on the safety and performance of this system.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 75
• Est. completion date: August 2025
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has severe mitral regurgitation

• New York Heart Association (NYHA) Class II, III, IVa or heart failure

• High risk for cardiovascular surgery

Exclusion Criteria:

• Excessive calcification or thickening of mitral valve annulus

• Severe mitral stenosis, fused commissures, valvular vegetation or mass

• Left ventricular end diastolic dimension > 7cm

• Left ventricular outflow tract obstruction

• Severe right ventricular dysfunction

• Stroke within 90 days; transient ischemic attack or myocardial infarction within 30 days of the index procedure

Related Conditions & MeSH terms

• Heart Diseases
• Heart Valve Diseases
• Mitral Disease
• Mitral Regurgitation
• Mitral Valve Disease
• Mitral Valve Failure
• Mitral Valve Insufficiency
• Valve Disease, Heart
• Valve Heart Disease

Intervention

Device:
• Transcatheter Mitral Valve Replacement
All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.

Locations

Country	Name	City	State
United States	Pennsylvania State University	Hershey	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Caisson Interventional LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients without Major Adverse Events (MAEs)	Freedom from major adverse events including death, stroke, myocardial infarction and surgical reintervention through 30 days	30 days
Secondary	Number of patients with successful delivery and implantation of the prosthetic valve (technical success)	Successful delivery and retrieval of the transcatheter mitral valve delivery system; deployment and correct positioning (via intraoperative imaging) in the appropriate anatomic location of prosthetic valve with no requirement for additional surgery	Intra-operative
Secondary	Number of living, stroke-free patients with prosthetic valve in place (device success)	Patient is alive, stroke-free, original intended device in place (echo), no mitral valve surgical re-intervention required	30 days